IL-2 therapy has also been evaluated in a clinical study treating hepatitis C virus (HCV), in which a strong increase in CD25+ FoxP3+ CD8+ Tregs was observed [88], a finding that could warrant further studies also in the context of atherosclerosis. The gene discussed is CD8A; the disease is atherosclerosis.